The lowered price target could potentially indicate a perceived decrease in Biora Therapeutics' future performance. However, the maintained 'Buy' rating suggests that the analyst still sees potential upside, which could balance out any negative sentiment from the lowered target. The short-term impact on the stock price is uncertain, hence the neutral score.